2023 World Conference on Lung Cancer (Posters)-EP12.01. Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis

EP12.01. Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis - PDF(Slides)

Back to course

Pdf Summary

This study investigated treatment strategies and survival outcomes of patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) and leptomeningeal metastasis (LM) after acquiring resistance to EGFR-Tyrosine Kinase Inhibitor (TKI). The study enrolled 75 patients with EGFR-mutated NSCLC and confirmed LM who received third-generation EGFR-TKI treatment after LM diagnosis. The patients were stratified into three groups based on their EGFR-TKI treatment history. The results showed that patients who received third-generation EGFR-TKI had an objective response rate (ORR) of 45.2% and a disease control rate (DCR) of 76.7%. The median overall survival (OS) after LM diagnosis was 12.2 months. Patients in Group 3, who had not received prior EGFR-TKI treatment, had a significantly better median OS compared to those in Group 2 and Group 1. High-dose third-generation EGFR-TKI showed improved OS in all three groups, although this effect was not statistically significant. Intrathecal chemotherapy significantly improved OS, and patients in Group 2 who received third-generation EGFR-TKI with bevacizumab had a longer OS compared to those without bevacizumab. Multivariate analysis identified inferior KPS score and baseline MRI positive findings as independent predictors for OS. The study concludes that high-dose third-generation EGFR-TKI is an effective treatment for NSCLC patients with EGFR mutation and LM, and the addition of intrathecal chemotherapy and third-generation EGFR TKI plus bevacizumab may further improve OS.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

treatment strategies

survival outcomes

EGFR-mutated NSCLC

leptomeningeal metastasis

third-generation EGFR-TKI

objective response rate

disease control rate

median overall survival

intrathecal chemotherapy

bevacizumab